Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 13/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.58 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10262260 | 0.81 | PNMT (0.59) | PNMTADRA2AADRA2BADRA2CGFER | |
| SCHEMBL10262098 | 0.81 | PNMT (0.51) | PNMTADRA2AADRA2BADRA2CCHRNB2 | |
| SCHEMBL12938097 | 0.80 | PNMT (0.66) | PNMTADRA2AADRA2BADRA2CGFER | |
| SCHEMBL31158806 | 0.77 | PNMT (0.67) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL31158866 | 0.77 | PNMT (0.67) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL13416396 | 0.77 | PNMT (0.67) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL12741563 | 0.77 | PNMT (0.67) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL10092704 | 0.76 | ADRA2A (0.41) | PNMTADRA2AADRA2BADRA2CCHRNB2 | |
| SCHEMBL13920370 | 0.75 | CHRNB2 (0.40) | PNMTADRA2AADRA2BADRA2CCHRNB2 | |
| SCHEMBL20883591 | 0.75 | PNMT (0.60) | PNMTADRA2AADRA2BADRA2CCHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217966-A1 | PHARMACEUTICAL COMPOSITION CONTAINING GLP-1 RECEPTOR AGONIST HAVING FUSED RING | SHIONOGI & CO., LTD. (JP) | 2024-07-04 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217966-A1 | PHARMACEUTICAL COMPOSITION CONTAINING GLP-1 RECEPTOR AGONIST HAVING FUSED RING | GLP1R, GIPR, GCGR | PNMT 4825/4885ADRA2A 231/4885ADRA2B 207/4885 |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | PNMT 3737/4885ADRA2A 3282/4885ADRA2B 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.